Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Pfizer NDA review for rheumatoid arthritis drug
Tofacitinib an investigational drug is an oral JAK inhibitor. The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in August 2012 for the
Tofacitinib an investigational drug is an oral JAK inhibitor. The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in August 2012 for the
Starpharma and Eli Lilly are working on many projects for the improvement in delivery of small molecule and protein-based pharmaceuticals, with the help of dendrimer technology by Starpharma.
The first randomized double-blind placebo-controlled Phase III Altitude study included patients with type 2 diabetes and renal impairment, to evaluate Rasilez/Tekturna for more than one year in a
iSPERSE is a novel inhaled dry powder delivery platform developed by Pulmatrix for use in the delivery of drugs via inhalation for local or systemic applications. The preclinical
ChemDiv is believed to make use of its expertise in drug discovery. Janssen or Tibotec will fund certain R&D costs of ChemDiv for every research project and ChemDiv
Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties, and is under investigation as a treatment for MS. The Tenere trial, which was a two-year, randomized, rater-blinded
Zalicus has drawn the remaining $8.5m from its $20m secured credit facility with Oxford Finance to fund ion channel clinical development. Zalicus CEO Mark Corrigan said they look
According to HUMC’s technology consultant, the US hospital will receive an estimated $8m overall in federal stimulus funds, $3m of that in 2011. The 328-bed hospital will receive
ForteBio will provide a range of innovative, label-free protein analysis instruments that will extend Pall’s capabilities in the biopharmaceuticals process monitoring market and in the protein research market.
ALKS 9070, a Alkermes molecule, is designed to provide once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available